Technical Analysis for NVAX - Novavax, Inc.

Grade Last Price % Change Price Change
D 176.24 -5.79% -10.83
NVAX closed down 5.79 percent on Wednesday, June 16, 2021, on 2.06 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down
Historical NVAX trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
20 DMA Support Bullish 0.00%
Spinning Top Other 0.00%
Multiple of Ten Bearish Other 0.00%
Multiple of Ten Bullish Other 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -5.79%
Multiple of Ten Bearish Other -5.79%
Wide Bands Range Expansion -5.79%
Older End-of-Day Signals for NVAX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Fell Below 20 DMA about 4 hours ago
Down 1 ATR about 4 hours ago
20 DMA Support about 4 hours ago
Trending on StockTwits about 7 hours ago
Down 5% about 7 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Novavax, Inc. Description

Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. The company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles (VLPs) and recombinant protein micelle vaccines. Its vaccine candidates target seasonal influenza, pandemic (H5N1) influenza, and respiratory syncytial virus (RSV). The company, through its joint venture, CPL Biologics Private Limited, engages in developing seasonal and pandemic influenza, and rabies vaccine candidates. The company has a licensing agreement with LG Life Sciences, Ltd. to use the company's VLP technology to develop and sell the influenza vaccines in South Korea and other countries; and a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Rockville, Maryland.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Development Infectious Diseases Influenza Coronavirus Vaccine Vaccination Influenza Vaccine Influenza Vaccines Rabies Seasonal Influenza Novavax

Is NVAX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 331.5388
52 Week Low 59.3
Average Volume 3,896,958
200-Day Moving Average 154.42
50-Day Moving Average 181.62
20-Day Moving Average 171.84
10-Day Moving Average 194.59
Average True Range 16.76
ADX 26.12
+DI 28.70
-DI 23.93
Chandelier Exit (Long, 3 ATRs) 179.23
Chandelier Exit (Short, 3 ATRs) 178.84
Upper Bollinger Bands 222.21
Lower Bollinger Band 121.48
Percent B (%b) 0.54
BandWidth 58.62
MACD Line 7.08
MACD Signal Line 4.06
MACD Histogram 3.0234
Fundamentals Value
Market Cap 11.22 Billion
Num Shares 63.7 Million
EPS -8.60
Price-to-Earnings (P/E) Ratio -20.50
Price-to-Sales 30.36
Price-to-Book 77.25
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 207.14
Resistance 3 (R3) 208.09 198.75 201.99
Resistance 2 (R2) 198.75 190.88 198.27 200.27
Resistance 1 (R1) 187.49 186.02 182.82 186.54 198.56
Pivot Point 178.15 178.15 175.81 177.67 178.15
Support 1 (S1) 166.89 170.28 162.22 165.94 153.92
Support 2 (S2) 157.55 165.42 157.07 152.21
Support 3 (S3) 146.29 157.55 150.49
Support 4 (S4) 145.34